<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Prenatal substance exposure and neonatal abstinence syndrome (NAS): Clinical features and diagnosis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Prenatal substance exposure and neonatal abstinence syndrome (NAS): Clinical features and diagnosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Prenatal substance exposure and neonatal abstinence syndrome (NAS): Clinical features and diagnosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lauren M Jansson, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joseph A Garcia-Prats, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carrie Armsby, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 24, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>An infant born to a person with a substance use disorder is at risk for withdrawal, commonly referred to as neonatal abstinence syndrome (NAS). NAS is a variable, complex, and incompletely understood spectrum of signs of neonatal neurobehavioral dysregulation.</p><p>Although most commonly associated with opioid exposure, other substances have been associated with an abstinence syndrome, including nicotine. Additionally, other substances, such as cigarettes, benzodiazepines, and selective serotonin reuptake inhibitors (SSRIs), can potentiate the severity of opioid-induced NAS.</p><p>Clinical features and evaluation of neonates with prenatal substance exposure and NAS will be reviewed here. Management and outcome of infants with prenatal substance exposure and NAS is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/5016.html" rel="external">"Prenatal substance exposure and neonatal abstinence syndrome (NAS): Management and outcomes"</a>.)</p><p>Other related topics are discussed separately, including:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4799.html" rel="external">"Substance use during pregnancy: Screening and prenatal care"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4790.html" rel="external">"Opioid use disorder: Overview of treatment during pregnancy"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4803.html" rel="external">"Cigarette and tobacco products in pregnancy: Impact on pregnancy and the neonate"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4798.html" rel="external">"Alcohol intake and pregnancy"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/87238.html" rel="external">"Opioid use disorder: Pharmacotherapy with methadone and buprenorphine during pregnancy"</a>.)</p><p></p><p class="headingAnchor" id="H3273645729"><span class="h1">DEFINITIONS AND TERMINOLOGY</span><span class="headingEndMark"> — </span>NAS is a clinical diagnosis based on the development of consistent clinical manifestations in an infant with prenatal substance exposure. (See  <a class="medical medical_review" href="/z/d/html/5016.html" rel="external">"Prenatal substance exposure and neonatal abstinence syndrome (NAS): Management and outcomes"</a>.)</p><p>Terminology continues to evolve for infants prenatally exposed to substances. For this discussion, we use the following terms:</p><p class="bulletIndent1"><span class="glyph">●</span>NAS – NAS describes neonates with withdrawal from in utero exposure to licit and illicit substances, including (but not limited to) opioids [<a href="#rid1">1,2</a>]. NAS can be associated with antenatal exposure to illicit opioids (eg, heroin), misuse of licit opioids (eg, <a class="external" href="%2Fcontents%2Foxycodone-pediatric-drug-information%3Fsearch%3Dneonatal%2Babstinence%2Bsyndrome%26topicRef%3D5016%26source%3Dsee_link&amp;data=02|01|Melanie.Kim%40wolterskluwer.com|949da5a2d2d14946d0d608d6ddff40ab|8ac76c91e7f141ffa89c3553b2da2c17|0|0|636940485701996856&amp;sdata=s0JmGRYga6K%2B8lQGfuEm7UBSXZ2FmEXtLjrMtTioitg%3D&amp;reserved=0" target="_blank">oxycodone</a>, <a class="external" href="%2Fcontents%2Ffentanyl-pediatric-drug-information%3Fsearch%3Dneonatal%2Babstinence%2Bsyndrome%26topicRef%3D5016%26source%3Dsee_link&amp;data=02|01|Melanie.Kim%40wolterskluwer.com|949da5a2d2d14946d0d608d6ddff40ab|8ac76c91e7f141ffa89c3553b2da2c17|0|0|636940485701996856&amp;sdata=4Fixd5K7fKIy2GksweSUb8jRlGJ0xi8gAbrCfIMAI7U%3D&amp;reserved=0" target="_blank">fentanyl</a>), or exposure to medications used to treat maternal opioid use disorder (<a class="external" href="%2Fcontents%2Fmethadone-pediatric-drug-information%3Fsearch%3Dneonatal%2Babstinence%2Bsyndrome%26topicRef%3D5016%26source%3Dsee_link&amp;data=02|01|Melanie.Kim%40wolterskluwer.com|949da5a2d2d14946d0d608d6ddff40ab|8ac76c91e7f141ffa89c3553b2da2c17|0|0|636940485702006865&amp;sdata=OL7a%2B1szK47o0OGsus9Q8%2BPOz0gZQiib3WfJ%2BXaLF2E%3D&amp;reserved=0" target="_blank">methadone</a> or <a class="external" href="%2Fcontents%2Fbuprenorphine-pediatric-drug-information%3Fsearch%3Dneonatal%2Babstinence%2Bsyndrome%26topicRef%3D5016%26source%3Dsee_link&amp;data=02|01|Melanie.Kim%40wolterskluwer.com|949da5a2d2d14946d0d608d6ddff40ab|8ac76c91e7f141ffa89c3553b2da2c17|0|0|636940485702006865&amp;sdata=S7ML28P1hm6SWKrPyaacDs8%2B6QxViTYWrjIYWY1BPGI%3D&amp;reserved=0" target="_blank">buprenorphine</a>) [<a href="#rid3">3,4</a>]. Characteristic clinical manifestations are discussed in detail below. (See <a class="local">'Presenting features'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Neonatal opioid withdrawal syndrome (NOWS) – NOWS describes neonates with withdrawal from in utero opioids <strong>only</strong>. NOWS is a subset of NAS [<a href="#rid5">5</a>]. However, it can be difficult to distinguish whether signs are due to withdrawal from opioids versus other substances (ie, nicotine, psychotropic medications), and thus NAS is used in this topic.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Iatrogenic NAS – Iatrogenic NAS refers to NAS occurring due to the therapeutic application of opioids for analgesia and sedation in infants; iatrogenic NAS will not be discussed here.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Opioid – The term opioid refers to natural and synthetic substances with morphine-like activities that activate mu-opioid receptors in the central nervous system and gastrointestinal tract.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Opiate – Opiate refers to a subclass of opioids consisting of alkaloid compounds extracted or derived from opium that includes <a class="drug drug_pediatric" data-topicid="16024" href="/z/d/drug information/16024.html" rel="external">morphine</a>, <a class="drug drug_pediatric" data-topicid="13178" href="/z/d/drug information/13178.html" rel="external">codeine</a>, and semisynthetic derivatives such as heroin, <a class="drug drug_pediatric" data-topicid="12590" href="/z/d/drug information/12590.html" rel="external">methadone</a>, <a class="drug drug_pediatric" data-topicid="13298" href="/z/d/drug information/13298.html" rel="external">fentanyl</a>, <a class="drug drug_pediatric" data-topicid="13364" href="/z/d/drug information/13364.html" rel="external">hydromorphone</a>, and <a class="drug drug_pediatric" data-topicid="12918" href="/z/d/drug information/12918.html" rel="external">buprenorphine</a>. (See  <a class="medical medical_review" href="/z/d/html/7804.html" rel="external">"Opioid use disorder: Epidemiology, clinical features, health consequences, screening, and assessment"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>NAS is a common issue in newborns. In the United States, the reported prevalence of NAS increased from 4.0 per 1000 birth hospitalizations in 2010 to 7.3 per 1000 birth hospitalizations in 2017 [<a href="#rid6">6</a>]. The specific rate of NAS varies across states, and in some states, the rate has decreased; data for each state are available from the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdatatools.ahrq.gov%2Fhcup-fast-stats%2F&amp;token=rF216vkTPeDC%2BhajdGWoudpCMWVFCdPXfKo%2FEbNNKfeWPXgmxtRy91zB2l2307d36xJPc%2BNiqdYrvXo6sV4yEg%3D%3D&amp;TOPIC_ID=5010" target="_blank">Healthcare Cost and Utilization Project database</a>.</p><p>The use and misuse of illicit and licit substances by pregnant people, and thus risk for NAS, has increased and is likely under reported [<a href="#rid7">7,8</a>]. In particular, the incidence of opioid use disorder (OUD) has increased in the United States, including among pregnant women, with a concomitant increase in NAS [<a href="#rid6">6</a>]. Cannabis use during pregnancy and lactation has also increased in the United States related to increasing legalization in the country [<a href="#rid9">9-12</a>].</p><p>Additionally, many pregnant and postpartum people use more than one substance [<a href="#rid13">13-22</a>]. In particular, people who use illicit drugs during pregnancy are more likely to concurrently smoke cigarettes and consume alcohol, which can also contribute to NAS manifestations. (See  <a class="medical medical_review" href="/z/d/html/4799.html" rel="external">"Substance use during pregnancy: Screening and prenatal care"</a>.)</p><p>Factors associated with prenatal stressors, including suboptimal treatment of substance use disorder, have also been associated with NAS. As an example, higher long-term unemployment and a shortage of mental health clinicians were associated with higher levels of NAS based on results from a 580 county-level study in eight states in the United States [<a href="#rid23">23</a>]. These data highlight the contribution of prenatal stressors to NAS expression. They also illustrate the need for efforts to comprehensively treat OUDs among childbearing people and to understand the social complexities related to opioid use and misuse during pregnancy and NAS. (See  <a class="medical medical_review" href="/z/d/html/4799.html" rel="external">"Substance use during pregnancy: Screening and prenatal care"</a> and  <a class="medical medical_review" href="/z/d/html/7804.html" rel="external">"Opioid use disorder: Epidemiology, clinical features, health consequences, screening, and assessment"</a> and  <a class="medical medical_review" href="/z/d/html/108803.html" rel="external">"Opioid use disorder: Treatment overview"</a>.)</p><p class="headingAnchor" id="H4061266476"><span class="h1">PATHOPHYSIOLOGY</span><span class="headingEndMark"> — </span>The pathophysiology of NAS and factors that influence its severity are not completely understood. However, altered levels of neurotransmitters such as norepinephrine, dopamine, and serotonin are presumed to play a significant role in NAS related to opioids and other substances [<a href="#rid24">24</a>].</p><p>For neonates with prenatal opioid exposure, genetic variations of the mu-opioid receptor (<em>OPRM1</em>) and the catechol-o-methyltransferase (<em>COMT</em>; encodes an enzyme that metabolizes catecholamines) genes appear to affect the need for pharmacotherapy and length of stay [<a href="#rid25">25</a>]. These data are consistent with data from adult studies that also show polymorphisms in these genes and are associated with variability in adult opioid dependence [<a href="#rid26">26</a>]. Epigenetic modifications to the mu-opioid receptor (<em>OPRM1</em>) promoter have also been associated with NAS severity [<a href="#rid27">27</a>].</p><p class="headingAnchor" id="H1650790922"><span class="h1">CLINICAL MANIFESTATIONS OF NAS</span></p><p class="headingAnchor" id="H1553812246"><span class="h2">Factors that affect presentation</span><span class="headingEndMark"> — </span>NAS presentation is widely variable in timing of onset and in the types and severity of signs displayed. This variability is likely multifactorial  (<a class="graphic graphic_table graphicRef142057" href="/z/d/graphic/142057.html" rel="external">table 1</a>) and is unique to each pregnancy. Maternal use of licit and illicit substances can affect presentation of NAS. Of note, studies have reported no association between the dose of medications to treat maternal opioid use disorder (OUD) (ie, <a class="drug drug_pediatric" data-topicid="12918" href="/z/d/drug information/12918.html" rel="external">buprenorphine</a>, <a class="drug drug_pediatric" data-topicid="12590" href="/z/d/drug information/12590.html" rel="external">methadone</a>) and NAS outcomes [<a href="#rid28">28-30</a>]. Factors which can cause poor maternal health and well-being during the pregnancy (eg, poor medical/obstetrical care, maternal stress, violence, poverty) can affect both the parent/caregivers' ability to respond to the infant and the infant's NAS manifestations. Environmental factors include the location of the infant's care (ie, rooming-in with parent/caregiver versus care in the neonatal intensive care unit) and caregivers' ability to appropriately handle and respond to the infant [<a href="#rid2">2,25,29-33</a>]. (See  <a class="medical medical_review" href="/z/d/html/4799.html" rel="external">"Substance use during pregnancy: Screening and prenatal care"</a> and  <a class="medical medical_review" href="/z/d/html/5016.html" rel="external">"Prenatal substance exposure and neonatal abstinence syndrome (NAS): Management and outcomes", section on 'Optimizing the care environment'</a>.)</p><p class="headingAnchor" id="H3246509429"><span class="h2">Presentations by substance</span></p><p class="headingAnchor" id="H3595656699"><span class="h3">Opioids</span></p><p class="headingAnchor" id="H1925456451"><span class="h4">Presenting features</span><span class="headingEndMark"> — </span>The characteristic signs of NAS reflect dysfunctional regulation in the central and autonomic nervous systems. The major domains of dysfunction include the following [<a href="#rid34">34-36</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>State control and attention – Sleep and wake cycle disturbances resulting in fragmented sleep with short sleep cycles and difficulty maintaining an alert state.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Motor and tone control – Alterations in tone or movement characterized by hypertonicity, tremors, and jitteriness.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Autonomic dysfunction – Sweating, sneezing, mottling, fever, nasal stuffiness, and frequent yawning.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sensory processing – Easy overstimulation, sensitivity, or hyperarousal resulting in irritability and crying (usually a high-pitched cry) with any stimuli. Infants may have tachypnea, gastrointestinal problems (gassiness, vomiting, loose stools), difficulties with feeding (suck-swallow incoordination), and oral hypersensitivities resulting in poor weight gain.</p><p></p><p>The presence and severity of these findings are the basis of assessment systems used in making management decisions in infants with NAS  (<a class="graphic graphic_form graphicRef55276" href="/z/d/graphic/55276.html" rel="external">form 1</a>). (See  <a class="medical medical_review" href="/z/d/html/5016.html" rel="external">"Prenatal substance exposure and neonatal abstinence syndrome (NAS): Management and outcomes", section on 'Ongoing assessment'</a>.)</p><p class="headingAnchor" id="H883293585"><span class="h4">Timing of onset</span><span class="headingEndMark"> — </span>Timing of the onset of NAS manifestations varies depending upon the recent history of exposures and the half-life of substance elimination. In infants exposed to heroin (short half-life), withdrawal signs often begin within 24 hours of birth, whereas withdrawal from longer-acting <a class="drug drug_pediatric" data-topicid="12590" href="/z/d/drug information/12590.html" rel="external">methadone</a> or <a class="drug drug_pediatric" data-topicid="12918" href="/z/d/drug information/12918.html" rel="external">buprenorphine</a> usually begins anywhere from 24 to 72 hours after birth [<a href="#rid2">2,24,37</a>]. For any opioids, withdrawal may be delayed until five days of age or later [<a href="#rid38">38</a>]. If one week or longer has elapsed between the last parental opioid use and delivery of the infant, the risk of acute signs of neonatal withdrawal is low [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H51662790"><span class="h4">Other sequelae present at birth</span><span class="headingEndMark"> — </span>Studies have demonstrated an association between exposure to opioids (including medications to treat opioid use disorder) and smaller head circumference and intrauterine growth restriction with low birth weight, although whether the relation is direct or driven by other factors is uncertain [<a href="#rid39">39-42</a>]. (See  <a class="medical medical_review" href="/z/d/html/5062.html" rel="external">"Infants with fetal (intrauterine) growth restriction"</a> and  <a class="medical medical_review" href="/z/d/html/2839.html" rel="external">"Microcephaly in infants and children: Etiology and evaluation", section on 'Etiology'</a>.)</p><p>In addition, multiple obstetric complications of opioid use during pregnancy can affect the fetus. These are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/128152.html" rel="external">"Substance use during pregnancy: Overview of selected drugs", section on 'Complications from use'</a>.)</p><p class="headingAnchor" id="H2029143940"><span class="h4">Impact of polysubstance exposure</span><span class="headingEndMark"> — </span>Polysubstance exposure can alter the presentation of NAS. Infants also exposed to cocaine, nicotine, or serotonin receptor inhibitors may have more severe opioid-induced neurobehavioral dysregulation [<a href="#rid43">43-46</a>]. Although data are limited, concurrent exposure to benzodiazepines, selective serotonin reuptake inhibitors (SSRIs), or <a class="drug drug_pediatric" data-topicid="13330" href="/z/d/drug information/13330.html" rel="external">gabapentin</a> can produce an atypical NAS in opioid-exposed infants [<a href="#rid47">47-50</a>].</p><p>As an example, in one case series of 19 neonates prenatally exposed to both opioids and <a class="drug drug_pediatric" data-topicid="13330" href="/z/d/drug information/13330.html" rel="external">gabapentin</a>, 15 demonstrated similar behaviors of wandering eye movements while awake, tongue thrusting, back arching, and continuous extremity movements [<a href="#rid49">49</a>].</p><p class="headingAnchor" id="H919062133"><span class="h4">Presentation in preterm infants</span><span class="headingEndMark"> — </span>Preterm infants have a lower incidence of NAS compared with term infants [<a href="#rid51">51</a>]. NAS manifestations severity diminishes as GA decreases [<a href="#rid14">14,33</a>]. However, scoring systems may not accurately reflect NAS signs in preterm infants, as they were designed to be used for term infants. Possible explanations of the reduced severity in preterm compared with term infants include [<a href="#rid8">8</a>]:</p><p class="bulletIndent2"><span class="glyph">•</span>Developmental immaturity of the preterm central nervous system</p><p class="bulletIndent2"><span class="glyph">•</span>Decreased receptor development and sensitivity</p><p class="bulletIndent2"><span class="glyph">•</span>Limited ability to express the signs of motor dysfunction</p><p class="bulletIndent2"><span class="glyph">•</span>Reduced total substance exposure during the intrauterine period</p><p class="bulletIndent2"><span class="glyph">•</span>Lower amounts of fat deposition of substance</p><p></p><p class="headingAnchor" id="H2432929318"><span class="h3">Cannabis</span><span class="headingEndMark"> — </span>Prenatal cannabis exposure has been associated with neurobehavioral dysregulation in the neonate as well as variable adverse effects in childhood, adolescence, and early adulthood (eg, cognitive deficits, high impulsivity) [<a href="#rid52">52,53</a>].</p><p>Although there are no data on a direct teratologic effect of prenatal cannabis exposure, indirect evidence has been reported showing an increased rate of congenital anomalies (cardiac and central nervous defects and Down syndrome) in areas with increased cannabis use during pregnancy (eg, Colorado) [<a href="#rid54">54</a>].</p><p>Negative effects of prenatal cannabis exposure on preterm birth, birth weight, and likelihood of transfer to the neonatal intensive care unit (NICU) are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/128152.html" rel="external">"Substance use during pregnancy: Overview of selected drugs", section on 'Cannabis (marijuana)'</a>.)</p><p class="headingAnchor" id="H1846434018"><span class="h3">Cocaine</span><span class="headingEndMark"> — </span>Newborn infants with prenatal cocaine exposure may exhibit neurobehavioral abnormalities which are most commonly noted between 48 and 72 hours of life [<a href="#rid8">8,55-57</a>]. In a prospective case-control study, infants known to be exposed only to cocaine compared with control infants were more likely to have central and autonomic neurologic manifestations, including [<a href="#rid55">55</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Tremors</p><p class="bulletIndent1"><span class="glyph">●</span>High-pitched cry</p><p class="bulletIndent1"><span class="glyph">●</span>Irritability</p><p class="bulletIndent1"><span class="glyph">●</span>Excess sucking</p><p class="bulletIndent1"><span class="glyph">●</span>Hyper-alertness</p><p class="bulletIndent1"><span class="glyph">●</span>Episodes of either apnea or tachypnea</p><p></p><p>There appears to be a dose-response relationship, with increased exposure resulting in increased neonatal hyperactivity and inability to orient to the environment [<a href="#rid58">58,59</a>]. Other studies have reported that cocaine-exposed infants within the first week of life have an increased rate of abnormal auditory brainstem responses and transient abnormal electroencephalographic (EEG) changes compared with nonexposed infants [<a href="#rid60">60,61</a>]. Prenatal cocaine exposure is associated with structural deficits in the infant brain, which has been associated with functional connectivity and neurobehavioral disruptions [<a href="#rid62">62-64</a>].</p><p>The effects of cocaine use during pregnancy and at delivery are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/128152.html" rel="external">"Substance use during pregnancy: Overview of selected drugs", section on 'Cocaine'</a>.)</p><p class="headingAnchor" id="H4154613766"><span class="h3">Amphetamines</span><span class="headingEndMark"> — </span>Amphetamines are addictive stimulants that can be misused or used as illicit drugs. Licit amphetamines include stimulants to treat attention-deficit hyperactivity disorder (ie, <a class="drug drug_pediatric" data-topicid="13218" href="/z/d/drug information/13218.html" rel="external">dextroamphetamine</a> and amphetamine, <a class="drug drug_pediatric" data-topicid="12600" href="/z/d/drug information/12600.html" rel="external">methylphenidate</a>). The most widely used illicit forms include methylenedioxymethamphetamine (MDMA; "ecstasy") and methamphetamine ("ice," "crystal").</p><p>It is unclear whether amphetamine exposure in utero causes withdrawal in the neonate. When reported, manifestations include shrill cry, irritability, jerkiness, diaphoresis, and sneezing [<a href="#rid65">65,66</a>]. However, such reports are limited by the inability to separate the effect of amphetamine alone from the effect of other substances used in utero and by the small number of reported patients. Furthermore, one large prospective study found no increase in neonatal withdrawal manifestations between methamphetamine-exposed neonates and matched controls [<a href="#rid67">67</a>].</p><p>Reported negative effects of prenatal amphetamine exposure on the fetus include prematurity and fetal growth restriction as well as fetal and neonatal death [<a href="#rid68">68-75</a>]. The risk of congenital anomalies with prenatal amphetamine exposure is uncertain [<a href="#rid76">76-78</a>]. These effects are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/128152.html" rel="external">"Substance use during pregnancy: Overview of selected drugs", section on 'Amphetamines, including methamphetamine'</a>.)</p><p class="headingAnchor" id="H1585949869"><span class="h3">Other substances</span><span class="headingEndMark"> — </span>Although neonatal neurobehavioral dysregulation is most commonly associated with opioid exposure, other substances may present with similar findings [<a href="#rid79">79-85</a>]. These include:</p><p class="bulletIndent2"><span class="glyph">•</span>Alcohol – Infants with fetal alcohol syndrome can experience withdrawals characterized by tremors, hypertonia, restlessness, excessive mouthing movements, inconsolable crying, and reflex abnormalities [<a href="#rid86">86</a>]. (See  <a class="medical medical_review" href="/z/d/html/14381.html" rel="external">"Fetal alcohol spectrum disorder: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/5411.html" rel="external">"Natural fertility and impact of lifestyle factors", section on 'Lifestyle effects on established pregnancy'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Benzodiazepines – Benzodiazepine-exposed infants can experience intoxication and withdrawal manifestations [<a href="#rid87">87,88</a>]. Signs include irritability, hypertonicity, tachypnea, vigorous sucking, hyperactivity, vomiting, loose stools, and poor weight gain. (See  <a class="medical medical_review" href="/z/d/html/17159.html" rel="external">"Teratogenicity, pregnancy complications, and postnatal risks of antipsychotics, benzodiazepines, lithium, and electroconvulsive therapy", section on 'Postnatal effects'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Nicotine – Nicotine-exposed infants can have withdrawal manifestations, including alterations in tone and alertness, and a greater need for handling and poorer self-regulation than infants not exposed to nicotine [<a href="#rid87">87-89</a>]. However, it is not clear if this is a transient drug effect versus a true withdrawal phenomenon [<a href="#rid90">90,91</a>]. Infants exposed to opioids and nicotine may have more severe NAS signs [<a href="#rid92">92</a>]. (See  <a class="medical medical_review" href="/z/d/html/4803.html" rel="external">"Cigarette and tobacco products in pregnancy: Impact on pregnancy and the neonate", section on 'Postnatal'</a>.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Psychotropic medications (eg, antidepressants or antipsychotics) – Infants exposed to psychotropic medications can have variable signs of withdrawal, including restlessness and sleeping and feeding difficulties [<a href="#rid93">93</a>]. These medications can also increase risk of opioid-induced withdrawal [<a href="#rid47">47</a>]. (See  <a class="medical medical_review" href="/z/d/html/5007.html" rel="external">"Antenatal exposure to selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs): Neonatal outcomes"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Kratom – Kratom is a product from the plant Mitragyna speciosa. It produces similar effects to opioids and has been used by some people as a recreational drug or to treat certain conditions, including pain [<a href="#rid94">94</a>]. Kratom-exposed infants can have withdrawal manifestations similar to those in opioid-exposed infants.</p><p></p><p class="headingAnchor" id="H2367630600"><span class="h2">Long-term outcomes of exposure</span><span class="headingEndMark"> — </span>The long-term outcomes of neonates exposed to prenatal substance use/misuse are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/5016.html" rel="external">"Prenatal substance exposure and neonatal abstinence syndrome (NAS): Management and outcomes", section on 'Long-term outcomes'</a>.)</p><p></p><p class="headingAnchor" id="H2074382584"><span class="h1">EVALUATION OF NAS</span></p><p class="headingAnchor" id="H2544778632"><span class="h2">Maternal screening</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Screening for substance use</strong> – All pregnant people should be screened for substance use/misuse at multiple points during the pregnancy and at the time of delivery, ideally by confidential interview. Routine universal obstetrical screening for use and misuse of licit and/or illicit substances is the main way to identify pregnant people in need of treatment for substance use disorder and neonates at risk for NAS. Unfortunately, pregnant people with substance use disorder often fear stigmatization and possible child removal [<a href="#rid95">95</a>]. Thus, it is important that screening occurs without pejorative attitudes or criminal sanctions. Screening and biologic testing for substance use/misuse during pregnancy is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/4799.html" rel="external">"Substance use during pregnancy: Screening and prenatal care", section on 'Screening for substance use'</a> and  <a class="medical medical_review" href="/z/d/html/4798.html" rel="external">"Alcohol intake and pregnancy"</a>.).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Screening for comorbid conditions</strong> – People with substance use/misuse should also be screened for comorbidities which can affect infant well-being, as they are at high risk for such conditions. These include sexually transmitted infections (ie, syphilis, chlamydia, gonorrhea, human immunodeficiency virus [HIV]), mental health concerns (ie, depression), and violence exposure [<a href="#rid2">2</a>]. Screening for conditions associated with substance use/misuse during pregnancy is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/4799.html" rel="external">"Substance use during pregnancy: Screening and prenatal care", section on 'Prenatal care of individuals with substance use disorder'</a>.)</p><p></p><p class="headingAnchor" id="H3158788476"><span class="h2">Clinical evaluation</span></p><p class="headingAnchor" id="H2813747587"><span class="h3">Neonates with known exposure</span><span class="headingEndMark"> — </span>For all neonates with known prenatal exposure to opioids or other substances (based on positive maternal screen), we assess for manifestations associated with NAS starting at birth and every four hours throughout the entire birth hospitalization. We use an abstinence scoring system  (<a class="graphic graphic_form graphicRef55276" href="/z/d/graphic/55276.html" rel="external">form 1</a>), which provides a semi-objective and standardized assessment of the withdrawal severity. Although the development of any manifestations associated with NAS (ie, irritability, poor sleep, jitteriness, hypertonicity, loose watery stools) in such neonates is likely related to withdrawal and supports the diagnosis of NAS, we also evaluate for and rule out other causes of such signs (ie, blood glucose to check for jitteriness due to hypoglycemia; sepsis evaluation for fevers, seizures). We also submit the first urine for toxicology testing. (See <a class="local">'Differential diagnosis'</a> below and <a class="local">'Neonatal screening'</a> below.)</p><p>Neonates with NAS should continue to undergo routine assessment of withdrawal severity, which informs the management approach. This is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/5016.html" rel="external">"Prenatal substance exposure and neonatal abstinence syndrome (NAS): Management and outcomes", section on 'Ongoing assessment'</a>.)</p><p>All neonates with substance exposure, regardless of whether they show clear withdrawal signs, benefit from nonpharmacologic approaches that are used to treat NAS. (See  <a class="medical medical_review" href="/z/d/html/5016.html" rel="external">"Prenatal substance exposure and neonatal abstinence syndrome (NAS): Management and outcomes", section on 'Managing individual manifestations'</a>.)</p><p class="headingAnchor" id="H604079169"><span class="h3">Neonates with consistent features but no known exposure</span><span class="headingEndMark"> — </span>NAS may be suspected in neonates whose presentation is highly consistent with withdrawal (ie, irritability, poor sleep, jitteriness, hypertonicity, loose watery stools) but were born to a person without confirmed substance use. NAS may also be suspected in neonates born to parents in whom substance use is suspected but not confirmed. In these cases, we assess the neonate for withdrawal severity  (<a class="graphic graphic_form graphicRef55276" href="/z/d/graphic/55276.html" rel="external">form 1</a>) as soon as the possibility of NAS is raised. In addition, we screen the parent again for substance use/misuse and evaluate the neonate for other causes of such manifestations.</p><p>Evaluation for other causes includes the following initial laboratory tests (see <a class="local">'Differential diagnosis'</a> below):</p><p class="bulletIndent1"><span class="glyph">●</span>Complete blood count – An elevated or markedly decreased white blood cell count may indicate systemic infection. Normal red blood cell count distinguishes NAS from polycythemia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serum glucose and calcium – Normal serum glucose and calcium distinguish NAS from hypoglycemia and hypocalcemia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Additional testing for certain patients includes:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For neonates in whom sepsis is a concern (ie, hyper- or hypothermia with irritability) – Blood cultures and empiric antibiotics (see  <a class="medical medical_review" href="/z/d/html/5046.html" rel="external">"Management and outcome of sepsis in term and late preterm neonates"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For neonates with clinical signs of hypothyroidism (ie, hypotonia, large tongue, large anterior fontanelle) – Thyroid function studies (see  <a class="medical medical_review" href="/z/d/html/5836.html" rel="external">"Clinical features and detection of congenital hypothyroidism"</a>)</p><p></p><p>A positive parental screen for substance use supports the diagnosis of NAS. Otherwise, we make a presumptive diagnosis of NAS if no alternate etiology is found. In both cases, we continue ongoing assessment for signs of withdrawal  (<a class="graphic graphic_form graphicRef55276" href="/z/d/graphic/55276.html" rel="external">form 1</a>) and send neonatal specimens for toxicology testing. Infrequently, neonatal testing may confirm the diagnosis of prenatal substance exposure in infants with signs of NAS and negative maternal screening. (See <a class="local">'Neonatal screening'</a> below.)</p><p class="headingAnchor" id="H3494593460"><span class="h2">Neonatal screening</span></p><p class="headingAnchor" id="H2821607067"><span class="h3">Toxicology screening</span><span class="headingEndMark"> — </span>Testing in neonates with prenatal substance exposure varies among institutions. At our institution, we send a first-void urine from all exposed neonates for toxicology screening. Although a positive screen for opioid (or other substances) in a neonatal specimen is not required to make the diagnosis of NAS, it can be helpful to confirm the diagnosis when uncertain or to document it. However, given testing limitations, a negative neonatal test does not rule out the possibility of NAS.</p><p>Neonatal testing can be done on an infant's first void, first meconium, or umbilical cord blood. Each test has clinical advantages and limitations [<a href="#rid2">2,8,32</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Urine – This is relatively easy to obtain and results from urine testing are rapid. However, urine screening of the newborn has a low sensitivity (high false-negative rate) because only recent exposure results in positive testing for most substances  (<a class="graphic graphic_table graphicRef95110" href="/z/d/graphic/95110.html" rel="external">table 2</a>) [<a href="#rid96">96</a>]. Thus, negative toxicology screening results do not rule out earlier exposures. Similarly, positive results may indicate one-time maternal use rather than a substance use disorder. Furthermore, urine toxicology screening does not detect prenatal alcohol exposure.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Meconium – Although results from meconium testing may take longer than a urine toxicology test, meconium analysis is sensitive and specific for substances that are excreted into the hepatobiliary system (eg, metabolites of heroin, cocaine, and cannabinoids) or intestinal tract [<a href="#rid13">13,97</a>]. Meconium analysis reflects exposures in the second and third trimesters. However, collection of appropriate meconium samples can be challenging, as meconium may be passed in utero or be contaminated with transitional stools. The delayed passage of meconium may result in a delayed diagnosis of substance exposure.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Umbilical cord blood and tissue – Testing of umbilical cord blood and tissue by using drug class-specific immunoassays appears to be a promising method of testing and is easier to collect than meconium [<a href="#rid98">98,99</a>]. However, its utility in medical management is limited because it does not quantify maternal use nor reflect periods of drug abstinence closer to delivery [<a href="#rid100">100,101</a>].</p><p></p><p>Although positive tests on neonatal toxicology screening indicate exposure in the infant, they cannot be used to diagnose substance use disorder in the parent. Urine tests reflect recent parental use but cannot quantify it. Meconium and umbilical cord assays reflect exposures in the second and third trimesters and so would not reflect periods of abstinence closer to term.</p><p>Of note, testing for both meconium and umbilical cord blood and tissue may not be available on-site at birth hospitals, and results from outside reference laboratories are often not received in time to affect management in the postpartum period.</p><p class="headingAnchor" id="H3621396263"><span class="h3">Screening for associated conditions</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Congenital infections</strong> – Substance-exposed neonates are screened for maternal infections including hepatitis, syphilis, and HIV, since infants born to mothers with substance use disorder are at higher risk for congenital infections [<a href="#rid55">55</a>]. (See  <a class="medical medical_review" href="/z/d/html/6011.html" rel="external">"Overview of TORCH infections"</a> and  <a class="medical medical_review" href="/z/d/html/13972.html" rel="external">"Prenatal evaluation of women with HIV in resource-rich settings"</a> and  <a class="medical medical_review" href="/z/d/html/4958.html" rel="external">"Hepatitis viruses and the newborn: Clinical manifestations and treatment"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Congenital malformations</strong> – Although there does appear to be an association between congenital malformations and prenatal substance exposure, most data are inconclusive [<a href="#rid102">102-110</a>]. An exception is the association between prenatal opioid exposure and cleft lip and/or palate, which has been reported in multiple observational studies [<a href="#rid102">102,105,106,111</a>]. Substance-exposed neonates are screened for congenital malformations by careful physical examination. Further evaluation (ie, with echocardiogram and/or sonogram) is needed if there is a concerning physical examination finding. (See  <a class="medical medical_review" href="/z/d/html/5774.html" rel="external">"Identifying newborns with critical congenital heart disease", section on 'Risk factors'</a>.)</p><p></p><p class="headingAnchor" id="H846753809"><span class="h1">DIAGNOSIS OF NAS</span></p><p class="headingAnchor" id="H518431755"><span class="h2">Diagnostic criteria</span><span class="headingEndMark"> — </span>For clinical purposes, we use an approach suggested by a panel of maternal and child health experts to make a working diagnosis of NAS, as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Diagnosis of NAS requires the presence of <strong>both</strong> of the following [<a href="#rid5">5</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Prenatal exposure to opioids, cannabis, or illicit substances, with or without other psychotropic substances, based on a positive maternal screen for substance use (either by history or by urine drug screening).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Two of the following five characteristic signs of substance withdrawal:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Excessive crying (ie, irritability).</p><p class="bulletIndent3"><span class="glyph">-</span>Fragmented sleep (ie, less than two to three hours at a time after feeding).</p><p class="bulletIndent3"><span class="glyph">-</span>Tremors (ie, jitteriness with or without being disturbed).</p><p class="bulletIndent3"><span class="glyph">-</span>Increased muscle tone (ie, muscle stiffness).</p><p class="bulletIndent3"><span class="glyph">-</span>Gastrointestinal dysfunction (ie, hyperphagia, poor feeding, feeding intolerance, loose or watery stools).</p><p></p><p>However, the approach to monitoring and nonpharmacologic management of neonates with in utero substance exposure is the same regardless of whether they meet the criteria above, as even infants without signs of NAS remain at risk for later development of NAS. The more clinically relevant criteria are those used to define the treatment threshold. This is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5016.html" rel="external">"Prenatal substance exposure and neonatal abstinence syndrome (NAS): Management and outcomes", section on 'Threshold for treatment'</a>.)</p><p class="headingAnchor" id="H1984116785"><span class="h2">Reporting the exposure/diagnosis</span><span class="headingEndMark"> — </span>Clinicians must be aware of the legal requirements needed for consent and for reporting when a diagnosis of prenatal substance exposure is made. Health care providers should be aware of state requirements for reporting substance use; decisions to report should be made in conjunction with social services providers based on the mother's/caregiver's available support/treatment structure and not on the presence of substance use alone [<a href="#rid112">112</a>]. Each birth institution should adopt a policy that complies with local laws and avoids discriminatory practices [<a href="#rid8">8</a>].</p><p>In the United States, the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.childwelfare.gov%2FpubPDFs%2Fparentalsubstanceuse.pdf&amp;token=Rti1NBSWdX%2F%2FH%2FlCKGrzlHQ93qlODhb77HGkOPCKRTOODfZhcRzGA%2BTTHDADYN6hp%2Fj8c4ekARa%2FMW3tm9Nv6CKi278OQ91dRY9R3Xup2Lo%3D&amp;TOPIC_ID=5010" target="_blank">Child Abuse Prevention and Treatment Act</a> requires health care professionals to facilitate referral of infants with prenatal substance use exposure and their caregivers to community-based, family support programs known as <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.childwelfare.gov%2FpubPDFs%2Fparentalsubstanceuse.pdf&amp;token=Rti1NBSWdX%2F%2FH%2FlCKGrzlHQ93qlODhb77HGkOPCKRTOODfZhcRzGA%2BTTHDADYN6hp%2Fj8c4ekARa%2FMW3tm9Nv6CKi278OQ91dRY9R3Xup2Lo%3D&amp;TOPIC_ID=5010" target="_blank">Plans of Safe Care</a>. These programs address the health and other needs of the infant and the substance use disorder treatment needs of the affected caregiver and others in the family [<a href="#rid113">113,114</a>]. The linked website provides a list for each state's reporting requirements and available plans of care.</p><p class="headingAnchor" id="H2353593123"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>Because other neonatal problems may have similar features to NAS, clinical signs should not be attributed solely to withdrawal without appropriate assessment and diagnostic tests to differentiate the following diseases from NAS:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Seizures</strong> – Neonates with seizures should have a complete diagnostic evaluation, as neonatal seizures can be seen in a number of conditions (ie, sepsis, meningitis, intraventricular hemorrhage, severe hypoglycemia). This is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/6152.html" rel="external">"Clinical features, evaluation, and diagnosis of neonatal seizures"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fever and irritability</strong> – Fever and irritability in a newborn with NAS should prompt evaluation for sepsis. Infectious illnesses are more common among substance-using/misusing populations, especially people who inject drugs. Therefore, substance-exposed infants are at increased risk for neonatal infections. Sepsis and fever in a neonate are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/5043.html" rel="external">"Clinical features, evaluation, and diagnosis of sepsis in term and late preterm neonates"</a> and  <a class="medical medical_review" href="/z/d/html/134347.html" rel="external">"The febrile neonate (28 days of age or younger): Outpatient evaluation and initial management", section on 'Evaluation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Irritability and poor weight gain</strong> – Irritability and poor weight gain can be seen in a number of neonatal conditions (ie, viral infection, congenital heart disease, inborn errors of metabolism). These are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/6467.html" rel="external">"Approach to the ill-appearing infant (younger than 90 days of age)"</a> and  <a class="medical medical_review" href="/z/d/html/129373.html" rel="external">"Ill-appearing infant (younger than 90 days of age): Causes"</a> and  <a class="medical medical_review" href="/z/d/html/5839.html" rel="external">"Evaluation and management of neonatal Graves disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Poor feeding</strong> – Poor feeding can also be a sign of anatomic or functional abnormalities; the approach to evaluating such patients is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/4976.html" rel="external">"Neonatal oral feeding difficulties due to sucking and swallowing disorders", section on 'Diagnostic evaluation'</a>.)</p><p></p><p class="headingAnchor" id="H182150651"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/83399.html" rel="external">"Patient education: Fetal alcohol syndrome (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/85731.html" rel="external">"Patient education: Alcohol and drug use in pregnancy (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H24"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definitions and terminology</strong> – NAS describes neonates with in utero exposure to licit and illicit substances, including opioids. Neonatal opioid withdrawal syndrome (NOWS) is a subset of NAS that describes neonates who have features of withdrawal from in utero opioids exposure specifically. (See <a class="local">'Definitions and terminology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations of NAS</strong> – Although the characteristic signs of NAS from many substances are similar, the clinical manifestations of NAS vary depending on the infant. Characteristic signs of NAS reflect dysfunctional regulation in the central and autonomic nervous systems, as follows (see <a class="local">'Clinical manifestations of NAS'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>State control and attention – Sleep and wake cycle disturbances result in fragmented sleep with short sleep cycles and difficulty maintaining an alert state.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Motor and tone control – Alterations in tone or movement are characterized by hypertonicity, tremors, and jitteriness.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Autonomic dysfunction – This manifests as sweating, sneezing, mottling, fever, nasal stuffiness, and frequent yawning.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Sensory processing – Easy overstimulation, sensitivity, or hyperarousal result in irritability and crying (usually a high-pitched cry) with any stimuli. Infants may have tachypnea, gastrointestinal problems (gassiness, vomiting, loose stools), difficulties with feeding (suck-swallow incoordination), and oral hypersensitivities resulting in poor weight gain.</p><p></p><p class="bulletIndent1">Newborns with prenatal cocaine exposure may present with episodes of apnea or tachypnea in addition to the manifestations listed above. (See <a class="local">'Cocaine'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Polysubstance exposure</strong> – Infants exposed to substances in addition to opioids can have an atypical NAS or more severe NAS than infants without polysubstance exposure. (See <a class="local">'Impact of polysubstance exposure'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preterm infants</strong> – Preterm infants have a lower incidence of NAS, but it is unclear if this is due to factors related to prematurity or to the inaccuracy of scoring systems to reflect NAS in preterm infants. (See <a class="local">'Presentation in preterm infants'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>For neonates with known prenatal substance exposure</strong>, we assess for signs associated with NAS starting at birth and every four hours throughout the entire birth hospitalization using an abstinence scoring system  (<a class="graphic graphic_form graphicRef55276" href="/z/d/graphic/55276.html" rel="external">form 1</a>). We also evaluate for and rule out other causes of such manifestations (ie, blood glucose to check for jitteriness due to hypoglycemia; sepsis evaluation for fevers, seizures). (See <a class="local">'Neonates with known exposure'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>For neonates with features of NAS but no known exposure</strong>, we assess the neonate for withdrawal severity  (<a class="graphic graphic_form graphicRef55276" href="/z/d/graphic/55276.html" rel="external">form 1</a>) as soon as the possibility of NAS is raised. We also screen the parent again for substance use/misuse and evaluate the neonate for other causes. (See <a class="local">'Neonates with consistent features but no known exposure'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Neonatal testing</strong> – We send all exposed neonates' first void for urine toxicology screening. A positive neonatal screen for opioid exposure is not required to make the diagnosis of NAS, and a negative neonatal test does not rule out the possibility of NAS in an exposed infant. Neonatal testing can be done on an infant's first void, first meconium, or umbilical cord blood. Testing protocols for exposed neonates vary among institutions. (See <a class="local">'Neonatal screening'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The clinical syndrome of NAS is nebulous and there are no specific, well-established diagnostic criteria for NAS. We use the following approach to make a working diagnosis of NAS, which requires the presence of <strong>both</strong> of the following (see <a class="local">'Diagnostic criteria'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Prenatal exposure to opioids, cannabis, or illicit substances, with or without other psychotropic substances, based on a positive maternal screen for substance use (either by history or by urine drug screening).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Two of the following five characteristic signs of substance withdrawal:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Excessive crying (ie, irritability).</p><p class="bulletIndent3"><span class="glyph">-</span>Fragmented sleep (ie, less than two to three hours at a time after feeding).</p><p class="bulletIndent3"><span class="glyph">-</span>Tremors (ie, jitteriness with or without being disturbed).</p><p class="bulletIndent3"><span class="glyph">-</span>Increased muscle tone (ie, muscle stiffness).</p><p class="bulletIndent3"><span class="glyph">-</span>Gastrointestinal dysfunction (ie, hyperphagia, poor feeding, feeding intolerance, loose or watery stools).</p><p></p><p class="bulletIndent1">The approach to monitoring and nonpharmacologic management of neonates with in utero substance exposure is the same regardless of whether they meet the criteria above, as even infants without signs of NAS remain at risk for later development of NAS. The more clinically relevant criteria are those used to define the treatment threshold. (See  <a class="medical medical_review" href="/z/d/html/5016.html" rel="external">"Prenatal substance exposure and neonatal abstinence syndrome (NAS): Management and outcomes", section on 'Threshold for treatment'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – Clinical signs of NAS should not be attributed solely to withdrawal without appropriate assessment and diagnostic tests because other neonatal problems may have similar features to NAS (ie, seizures, fever/irritability, poor weight gain). (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Devlin LA, Davis JM. A Practical Approach to Neonatal Opiate Withdrawal Syndrome. Am J Perinatol 2018; 35:324.</a></li><li><a class="nounderline abstract_t">Patrick SW, Barfield WD, Poindexter BB, COMMITTEE ON FETUS AND NEWBORN, COMMITTEE ON SUBSTANCE USE AND PREVENTION. Neonatal Opioid Withdrawal Syndrome. Pediatrics 2020; 146.</a></li><li><a class="nounderline abstract_t">Kandall SR, Albin S, Gartner LM, et al. The narcotic-dependent mother: fetal and neonatal consequences. Early Hum Dev 1977; 1:159.</a></li><li><a class="nounderline abstract_t">Jones HE, Kaltenbach K, Heil SH, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med 2010; 363:2320.</a></li><li><a class="nounderline abstract_t">Jilani SM, Jones HE, Grossman M, et al. Standardizing the Clinical Definition of Opioid Withdrawal in the Neonate. J Pediatr 2022; 243:33.</a></li><li><a class="nounderline abstract_t">Hirai AH, Ko JY, Owens PL, et al. Neonatal Abstinence Syndrome and Maternal Opioid-Related Diagnoses in the US, 2010-2017. JAMA 2021; 325:146.</a></li><li class="breakAll">2021 National Survey of Drug Use and Health (NSDUH) Releases. Substance Abuse and Mental Health Services Administration (SAMHSA). Available at: https://www.samhsa.gov/data/release/2021-national-survey-drug-use-and-health-nsduh-releases (Accessed on January 30, 2023).</li><li><a class="nounderline abstract_t">Hudak ML, Tan RC, COMMITTEE ON DRUGS, et al. Neonatal drug withdrawal. Pediatrics 2012; 129:e540.</a></li><li><a class="nounderline abstract_t">Haight SC, Ko JY, Tong VT, et al. Opioid Use Disorder Documented at Delivery Hospitalization - United States, 1999-2014. MMWR Morb Mortal Wkly Rep 2018; 67:845.</a></li><li><a class="nounderline abstract_t">Brown QL, Sarvet AL, Shmulewitz D, et al. Trends in Marijuana Use Among Pregnant and Nonpregnant Reproductive-Aged Women, 2002-2014. JAMA 2017; 317:207.</a></li><li><a class="nounderline abstract_t">Ko JY, Farr SL, Tong VT, et al. Prevalence and patterns of marijuana use among pregnant and nonpregnant women of reproductive age. Am J Obstet Gynecol 2015; 213:201.e1.</a></li><li><a class="nounderline abstract_t">Ryan SA, Ammerman SD, O'Connor ME, et al. Marijuana Use During Pregnancy and Breastfeeding: Implications for Neonatal and Childhood Outcomes. Pediatrics 2018; 142.</a></li><li><a class="nounderline abstract_t">Ostrea EM Jr, Brady MJ, Parks PM, et al. Drug screening of meconium in infants of drug-dependent mothers: an alternative to urine testing. J Pediatr 1989; 115:474.</a></li><li><a class="nounderline abstract_t">Doberczak TM, Kandall SR, Wilets I. Neonatal opiate abstinence syndrome in term and preterm infants. J Pediatr 1991; 118:933.</a></li><li><a class="nounderline abstract_t">Alroomi LG, Davidson J, Evans TJ, et al. Maternal narcotic abuse and the newborn. Arch Dis Child 1988; 63:81.</a></li><li><a class="nounderline abstract_t">Lam SK, To WK, Duthie SJ, Ma HK. Narcotic addiction in pregnancy with adverse maternal and perinatal outcome. Aust N Z J Obstet Gynaecol 1992; 32:216.</a></li><li><a class="nounderline abstract_t">Fricker HS, Segal S. Narcotic addiction, pregnancy, and the newborn. Am J Dis Child 1978; 132:360.</a></li><li><a class="nounderline abstract_t">Maas U, Kattner E, Weingart-Jesse B, et al. Infrequent neonatal opiate withdrawal following maternal methadone detoxification during pregnancy. J Perinat Med 1990; 18:111.</a></li><li><a class="nounderline abstract_t">Ebrahim SH, Gfroerer J. Pregnancy-related substance use in the United States during 1996-1998. Obstet Gynecol 2003; 101:374.</a></li><li><a class="nounderline abstract_t">Vega WA, Kolody B, Hwang J, Noble A. Prevalence and magnitude of perinatal substance exposures in California. N Engl J Med 1993; 329:850.</a></li><li><a class="nounderline abstract_t">Shor S, Nulman I, Kulaga V, Koren G. Heavy in utero ethanol exposure is associated with the use of other drugs of abuse in a high-risk population. Alcohol 2010; 44:623.</a></li><li><a class="nounderline abstract_t">Bakhireva LN, Shrestha S, Garrison L, et al. Prevalence of alcohol use in pregnant women with substance use disorder. Drug Alcohol Depend 2018; 187:305.</a></li><li><a class="nounderline abstract_t">Patrick SW, Faherty LJ, Dick AW, et al. Association Among County-Level Economic Factors, Clinician Supply, Metropolitan or Rural Location, and Neonatal Abstinence Syndrome. JAMA 2019; 321:385.</a></li><li><a class="nounderline abstract_t">Kocherlakota P. Neonatal abstinence syndrome. Pediatrics 2014; 134:e547.</a></li><li><a class="nounderline abstract_t">Wachman EM, Hayes MJ, Brown MS, et al. Association of OPRM1 and COMT single-nucleotide polymorphisms with hospital length of stay and treatment of neonatal abstinence syndrome. JAMA 2013; 309:1821.</a></li><li><a class="nounderline abstract_t">Mague SD, Blendy JA. OPRM1 SNP (A118G): involvement in disease development, treatment response, and animal models. Drug Alcohol Depend 2010; 108:172.</a></li><li><a class="nounderline abstract_t">Wachman EM, Hayes MJ, Lester BM, et al. Epigenetic variation in the mu-opioid receptor gene in infants with neonatal abstinence syndrome. J Pediatr 2014; 165:472.</a></li><li><a class="nounderline abstract_t">Seligman NS, Almario CV, Hayes EJ, et al. Relationship between maternal methadone dose at delivery and neonatal abstinence syndrome. J Pediatr 2010; 157:428.</a></li><li><a class="nounderline abstract_t">Wong J, Saver B, Scanlan JM, et al. Does Maternal Buprenorphine Dose Affect Severity or Incidence of Neonatal Abstinence Syndrome? J Addict Med 2018; 12:435.</a></li><li><a class="nounderline abstract_t">O'Connor AB, O'Brien L, Alto WA. Maternal Buprenorphine Dose at Delivery and Its Relationship to Neonatal Outcomes. Eur Addict Res 2016; 22:127.</a></li><li><a class="nounderline abstract_t">Jansson LM, Velez M. Neonatal abstinence syndrome. Curr Opin Pediatr 2012; 24:252.</a></li><li><a class="nounderline abstract_t">Bio LL, Siu A, Poon CY. Update on the pharmacologic management of neonatal abstinence syndrome. J Perinatol 2011; 31:692.</a></li><li><a class="nounderline abstract_t">Liu AJ, Jones MP, Murray H, et al. Perinatal risk factors for the neonatal abstinence syndrome in infants born to women on methadone maintenance therapy. Aust N Z J Obstet Gynaecol 2010; 50:253.</a></li><li><a class="nounderline abstract_t">Velez M, Jansson LM. The Opioid dependent mother and newborn dyad: non-pharmacologic care. J Addict Med 2008; 2:113.</a></li><li><a class="nounderline abstract_t">Velez ML, Jordan CJ, Jansson LM. Reconceptualizing non-pharmacologic approaches to Neonatal Abstinence Syndrome (NAS) and Neonatal Opioid Withdrawal Syndrome (NOWS): A theoretical and evidence-based approach. Neurotoxicol Teratol 2021; 88:107020.</a></li><li><a class="nounderline abstract_t">Velez ML, Jordan C, Jansson LM. Reconceptualizing non-pharmacologic approaches to Neonatal Abstinence Syndrome (NAS) and Neonatal Opioid Withdrawal Syndrome (NOWS): A theoretical and evidence-based approach. Part II: The clinical application of nonpharmacologic care for NAS/NOWS. Neurotoxicol Teratol 2021; 88:107032.</a></li><li><a class="nounderline abstract_t">Zelson C, Rubio E, Wasserman E. Neonatal narcotic addiction: 10 year observation. Pediatrics 1971; 48:178.</a></li><li><a class="nounderline abstract_t">Kandall SR, Gartner LM. Late presentation of drug withdrawal symptoms in newborns. Am J Dis Child 1974; 127:58.</a></li><li><a class="nounderline abstract_t">Liu AJ, Sithamparanathan S, Jones MP, et al. Growth restriction in pregnancies of opioid-dependent mothers. Arch Dis Child Fetal Neonatal Ed 2010; 95:F258.</a></li><li><a class="nounderline abstract_t">Towers CV, Hyatt BW, Visconti KC, et al. Neonatal Head Circumference in Newborns With Neonatal Abstinence Syndrome. Pediatrics 2019; 143.</a></li><li><a class="nounderline abstract_t">Cutler AJ, Cox DF, Gabrielson SMB, et al. Association of medication-assisted treatment and short acting opioids with newborn head circumference and birth weight. J Perinatol 2023; 43:277.</a></li><li class="breakAll">Published comments: Towers CV et al. Neonatal Head Circumference in Newborns With Neonatal Abstinence Syndrome. Pediatircs 2019. http://pediatrics.aappublications.org/content/143/1/e20180541.comments (Accessed on February 05, 2019).</li><li><a class="nounderline abstract_t">Jansson LM, Di Pietro JA, Elko A, et al. Pregnancies exposed to methadone, methadone and other illicit substances, and poly-drugs without methadone: a comparison of fetal neurobehaviors and infant outcomes. Drug Alcohol Depend 2012; 122:213.</a></li><li><a class="nounderline abstract_t">Mayes LC, Carroll KM. Neonatal withdrawal syndrome in infants exposed to cocaine and methadone. Subst Use Misuse 1996; 31:241.</a></li><li><a class="nounderline abstract_t">Choo RE, Huestis MA, Schroeder JR, et al. Neonatal abstinence syndrome in methadone-exposed infants is altered by level of prenatal tobacco exposure. Drug Alcohol Depend 2004; 75:253.</a></li><li><a class="nounderline abstract_t">Wachman EM, Newby PK, Vreeland J, et al. The relationship between maternal opioid agonists and psychiatric medications on length of hospitalization for neonatal abstinence syndrome. J Addict Med 2011; 5:293.</a></li><li><a class="nounderline abstract_t">Huybrechts KF, Bateman BT, Desai RJ, et al. Risk of neonatal drug withdrawal after intrauterine co-exposure to opioids and psychotropic medications: cohort study. BMJ 2017; 358:j3326.</a></li><li><a class="nounderline abstract_t">Sanlorenzo LA, Cooper WO, Dudley JA, et al. Increased Severity of Neonatal Abstinence Syndrome Associated With Concomitant Antenatal Opioid and Benzodiazepine Exposure. Hosp Pediatr 2019; 9:569.</a></li><li><a class="nounderline abstract_t">Loudin S, Murray S, Prunty L, et al. An Atypical Withdrawal Syndrome in Neonates Prenatally Exposed to Gabapentin and Opioids. J Pediatr 2017; 181:286.</a></li><li><a class="nounderline abstract_t">DeLisle A, Jones HE, Jansson LM. Gabapentin Use During Pregnancy and Lactation With and Without Concurrent Opioid Exposure: Considerations and Future Directions. J Addict Med 2023; 17:123.</a></li><li><a class="nounderline abstract_t">Dysart K, Hsieh HC, Kaltenbach K, Greenspan JS. Sequela of preterm versus term infants born to mothers on a methadone maintenance program: differential course of neonatal abstinence syndrome. J Perinat Med 2007; 35:344.</a></li><li><a class="nounderline abstract_t">de Moraes Barros MC, Guinsburg R, de Araújo Peres C, et al. Exposure to marijuana during pregnancy alters neurobehavior in the early neonatal period. J Pediatr 2006; 149:781.</a></li><li><a class="nounderline abstract_t">Navarrete F, García-Gutiérrez MS, Gasparyan A, et al. Cannabis Use in Pregnant and Breastfeeding Women: Behavioral and Neurobiological Consequences. Front Psychiatry 2020; 11:586447.</a></li><li><a class="nounderline abstract_t">Reece AS, Hulse GK. Cannabis Teratology Explains Current Patterns of Coloradan Congenital Defects: The Contribution of Increased Cannabinoid Exposure to Rising Teratological Trends. Clin Pediatr (Phila) 2019; 58:1085.</a></li><li><a class="nounderline abstract_t">Bauer CR, Langer JC, Shankaran S, et al. Acute neonatal effects of cocaine exposure during pregnancy. Arch Pediatr Adolesc Med 2005; 159:824.</a></li><li><a class="nounderline abstract_t">Eyler FD, Behnke M, Garvan CW, et al. Newborn evaluations of toxicity and withdrawal related to prenatal cocaine exposure. Neurotoxicol Teratol 2001; 23:399.</a></li><li><a class="nounderline abstract_t">Chasnoff IJ, Bussey ME, Savich R, Stack CM. Perinatal cerebral infarction and maternal cocaine use. J Pediatr 1986; 108:456.</a></li><li><a class="nounderline abstract_t">Eyler FD, Behnke M, Conlon M, et al. Birth outcome from a prospective, matched study of prenatal crack/cocaine use: II. Interactive and dose effects on neurobehavioral assessment. Pediatrics 1998; 101:237.</a></li><li><a class="nounderline abstract_t">Chiriboga CA, Brust JC, Bateman D, Hauser WA. Dose-response effect of fetal cocaine exposure on newborn neurologic function. Pediatrics 1999; 103:79.</a></li><li><a class="nounderline abstract_t">Tan-Laxa MA, Sison-Switala C, Rintelman W, Ostrea EM Jr. Abnormal auditory brainstem response among infants with prenatal cocaine exposure. Pediatrics 2004; 113:357.</a></li><li><a class="nounderline abstract_t">Doberczak TM, Shanzer S, Senie RT, Kandall SR. Neonatal neurologic and electroencephalographic effects of intrauterine cocaine exposure. J Pediatr 1988; 113:354.</a></li><li><a class="nounderline abstract_t">Grewen K, Burchinal M, Vachet C, et al. Prenatal cocaine effects on brain structure in early infancy. Neuroimage 2014; 101:114.</a></li><li><a class="nounderline abstract_t">Salzwedel AP, Grewen KM, Vachet C, et al. Prenatal drug exposure affects neonatal brain functional connectivity. J Neurosci 2015; 35:5860.</a></li><li><a class="nounderline abstract_t">Salzwedel AP, Grewen KM, Goldman BD, Gao W. Thalamocortical functional connectivity and behavioral disruptions in neonates with prenatal cocaine exposure. Neurotoxicol Teratol 2016; 56:16.</a></li><li><a class="nounderline abstract_t">Eriksson M, Larsson G, Winbladh B, Zetterström R. The influence of amphetamine addiction on pregnancy and the newborn infant. Acta Paediatr Scand 1978; 67:95.</a></li><li><a class="nounderline abstract_t">Ramer CM. The case history of an infant born to an amphetamine-addicted mother. Clin Pediatr (Phila) 1974; 13:596.</a></li><li><a class="nounderline abstract_t">Kiblawi ZN, Smith LM, Diaz SD, et al. Prenatal methamphetamine exposure and neonatal and infant neurobehavioral outcome: results from the IDEAL study. Subst Abus 2014; 35:68.</a></li><li><a class="nounderline abstract_t">Smith L, Yonekura ML, Wallace T, et al. Effects of prenatal methamphetamine exposure on fetal growth and drug withdrawal symptoms in infants born at term. J Dev Behav Pediatr 2003; 24:17.</a></li><li><a class="nounderline abstract_t">Hansen RL, Struthers JM, Gospe SM Jr. Visual evoked potentials and visual processing in stimulant drug-exposed infants. Dev Med Child Neurol 1993; 35:798.</a></li><li><a class="nounderline abstract_t">Oei JL, Kingsbury A, Dhawan A, et al. Amphetamines, the pregnant woman and her children: a review. J Perinatol 2012; 32:737.</a></li><li><a class="nounderline abstract_t">Smith LM, LaGasse LL, Derauf C, et al. The infant development, environment, and lifestyle study: effects of prenatal methamphetamine exposure, polydrug exposure, and poverty on intrauterine growth. Pediatrics 2006; 118:1149.</a></li><li><a class="nounderline abstract_t">Wright TE, Schuetter R, Tellei J, Sauvage L. Methamphetamines and pregnancy outcomes. J Addict Med 2015; 9:111.</a></li><li><a class="nounderline abstract_t">Nguyen D, Smith LM, Lagasse LL, et al. Intrauterine growth of infants exposed to prenatal methamphetamine: results from the infant development, environment, and lifestyle study. J Pediatr 2010; 157:337.</a></li><li><a class="nounderline abstract_t">Arria AM, Derauf C, Lagasse LL, et al. Methamphetamine and other substance use during pregnancy: preliminary estimates from the Infant Development, Environment, and Lifestyle (IDEAL) study. Matern Child Health J 2006; 10:293.</a></li><li><a class="nounderline abstract_t">Kalaitzopoulos DR, Chatzistergiou K, Amylidi AL, et al. Effect of Methamphetamine Hydrochloride on Pregnancy Outcome: A Systematic Review and Meta-analysis. J Addict Med 2018; 12:220.</a></li><li class="breakAll">Heinonen OP. Birth Defects and Drugs in Pregnancy, Publishing Sciences Group, Inc, Littleton, MA 1977.</li><li><a class="nounderline abstract_t">Milkovich L, van der Berg BJ. Effects of antenatal exposure to anorectic drugs. Am J Obstet Gynecol 1977; 129:637.</a></li><li><a class="nounderline abstract_t">Nelson MM, Forfar JO. Associations between drugs administered during pregnancy and congenital abnormalities of the fetus. Br Med J 1971; 1:523.</a></li><li><a class="nounderline abstract_t">Pierog S, Chandavasu O, Wexler I. Withdrawal symptoms in infants with the fetal alcohol syndrome. J Pediatr 1977; 90:630.</a></li><li><a class="nounderline abstract_t">Robe LB, Gromisch DS, Iosub S. Symptoms of neonatal ethanol withdrawal. Curr Alcohol 1981; 8:485.</a></li><li><a class="nounderline abstract_t">Wikner BN, Stiller CO, Bergman U, et al. Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: neonatal outcome and congenital malformations. Pharmacoepidemiol Drug Saf 2007; 16:1203.</a></li><li><a class="nounderline abstract_t">Iqbal MM, Sobhan T, Ryals T. Effects of commonly used benzodiazepines on the fetus, the neonate, and the nursing infant. Psychiatr Serv 2002; 53:39.</a></li><li><a class="nounderline abstract_t">Pichini S, Garcia-Algar O. In utero exposure to smoking and newborn neurobehavior: how to assess neonatal withdrawal syndrome? Ther Drug Monit 2006; 28:288.</a></li><li><a class="nounderline abstract_t">Gentile S. On categorizing gestational, birth, and neonatal complications following late pregnancy exposure to antidepressants: the prenatal antidepressant exposure syndrome. CNS Spectr 2010; 15:167.</a></li><li class="breakAll">Sinclair L. Antipsychotic labels to cite risks to newborns. Psychiatric News 2011; 46:12. http://psychnews.psychiatryonline.org/newsarticle.aspx?articleid=108442 (Accessed on April 08, 2013).</li><li><a class="nounderline abstract_t">Coles CD, Smith IE, Fernhoff PM, Falek A. Neonatal ethanol withdrawal: characteristics in clinically normal, nondysmorphic neonates. J Pediatr 1984; 105:445.</a></li><li><a class="nounderline abstract_t">Rementería JL, Bhatt K. Withdrawal symptoms in neonates from intrauterine exposure to diazepam. J Pediatr 1977; 90:123.</a></li><li><a class="nounderline abstract_t">Ordean A, Chisamore B. Clinical presentation and management of neonatal abstinence syndrome: an update. Dove Medical Press 2014; 4:75.</a></li><li><a class="nounderline abstract_t">Godding V, Bonnier C, Fiasse L, et al. Does in utero exposure to heavy maternal smoking induce nicotine withdrawal symptoms in neonates? Pediatr Res 2004; 55:645.</a></li><li><a class="nounderline abstract_t">Liska SR. In utero exposure to Black Bull chewing tobacco and neonatal nicotine withdrawal: a review of the literature. Neonatal Netw 2014; 33:5.</a></li><li><a class="nounderline abstract_t">Behnke M, Smith VC, Committee on Substance Abuse, Committee on Fetus and Newborn. Prenatal substance abuse: short- and long-term effects on the exposed fetus. Pediatrics 2013; 131:e1009.</a></li><li><a class="nounderline abstract_t">Isaacs KR, Atreyapurapu S, Alyusuf AH, et al. Neonatal Outcomes after Combined Opioid and Nicotine Exposure in Utero: A Scoping Review. Int J Environ Res Public Health 2021; 18.</a></li><li><a class="nounderline abstract_t">Kieviet N, Dolman K, Wennink H, et al. [Withdrawal in newborns after exposure to psychotropic medications during pregnancy]. Ned Tijdschr Geneeskd 2012; 156:A4395.</a></li><li><a class="nounderline abstract_t">Wright ME, Ginsberg C, Parkison AM, et al. Outcomes of mothers and newborns to prenatal exposure to kratom: a systematic review. J Perinatol 2021; 41:1236.</a></li><li><a class="nounderline abstract_t">Committee Opinion No. 711: Opioid Use and Opioid Use Disorder in Pregnancy. Obstet Gynecol 2017; 130:e81.</a></li><li class="breakAll">Marijuana Drug Test Detection Times. www.canorml.org/healthfacts/drugtestguide/drugtestdetection.html (Accessed on February 17, 2016).</li><li><a class="nounderline abstract_t">Ostrea EM Jr, Knapp DK, Tannenbaum L, et al. Estimates of illicit drug use during pregnancy by maternal interview, hair analysis, and meconium analysis. J Pediatr 2001; 138:344.</a></li><li><a class="nounderline abstract_t">Kyle AR, Carmical J, Shah D, et al. UHPLC-MS/MS quantification of buprenorphine, norbuprenorphine, methadone, and glucuronide conjugates in umbilical cord plasma. Biomed Chromatogr 2015; 29:1567.</a></li><li><a class="nounderline abstract_t">Montgomery D, Plate C, Alder SC, et al. Testing for fetal exposure to illicit drugs using umbilical cord tissue vs meconium. J Perinatol 2006; 26:11.</a></li><li class="breakAll">United States Drug Testing Laboratory (www.usdtl.com) (Accessed on January 02, 2014).</li><li><a class="nounderline abstract_t">Colby JM, Adams BC, Morad A, et al. Umbilical Cord Tissue and Meconium May Not Be Equivalent for Confirming in Utero Substance Exposure. J Pediatr 2019; 205:277.</a></li><li><a class="nounderline abstract_t">Bateman BT, Hernandez-Diaz S, Straub L, et al. Association of first trimester prescription opioid use with congenital malformations in the offspring: population based cohort study. BMJ 2021; 372:n102.</a></li><li><a class="nounderline abstract_t">McGlone L, Mactier H. Infants of opioid-dependent mothers: neurodevelopment at six months. Early Hum Dev 2015; 91:19.</a></li><li><a class="nounderline abstract_t">Yoo SH, Jansson LM, Park HJ. Sensorimotor outcomes in children with prenatal exposure to methadone. J AAPOS 2017; 21:316.</a></li><li><a class="nounderline abstract_t">Interrante JD, Ailes EC, Lind JN, et al. Risk comparison for prenatal use of analgesics and selected birth defects, National Birth Defects Prevention Study 1997-2011. Ann Epidemiol 2017; 27:645.</a></li><li><a class="nounderline abstract_t">Lind JN, Interrante JD, Ailes EC, et al. Maternal Use of Opioids During Pregnancy and Congenital Malformations: A Systematic Review. Pediatrics 2017; 139.</a></li><li><a class="nounderline abstract_t">Yazdy MM, Mitchell AA, Tinker SC, et al. Periconceptional use of opioids and the risk of neural tube defects. Obstet Gynecol 2013; 122:838.</a></li><li><a class="nounderline abstract_t">Broussard CS, Rasmussen SA, Reefhuis J, et al. Maternal treatment with opioid analgesics and risk for birth defects. Am J Obstet Gynecol 2011; 204:314.e1.</a></li><li><a class="nounderline abstract_t">Wen X, Lawal OD, Belviso N, et al. Association Between Prenatal Opioid Exposure and Neurodevelopmental Outcomes in Early Childhood: A Retrospective Cohort Study. Drug Saf 2021; 44:863.</a></li><li><a class="nounderline abstract_t">Bowie AC, Werler MM, Velez MP, et al. Prescribed opioid analgesics in early pregnancy and the risk of congenital anomalies: a population-based cohort study. CMAJ 2022; 194:E152.</a></li><li><a class="nounderline abstract_t">Langa O, Cappitelli AT, Ganske IM. Cleft Lip and Palate in Infants With Prenatal Opioid Exposure. Cleft Palate Craniofac J 2022; 59:497.</a></li><li><a class="nounderline abstract_t">Krans EE, Campopiano M, Cleveland LM, et al. National Partnership for Maternal Safety: Consensus Bundle on Obstetric Care for Women With Opioid Use Disorder. Obstet Gynecol 2019; 134:365.</a></li><li class="breakAll">https://cff-cav56vrdcl.netdna-ssl.com/wp-content/uploads/2020/05/Judicial_Officers_POSC_Brief-1.pdf (Accessed on July 28, 2021).</li><li class="breakAll">https://cff-cav56vrdcl.netdna-ssl.com/wp-content/uploads/2020/05/Judicial_Officers_POSC_Brief-1.pdf (Accessed on July 23, 2021).</li></ol></div><div id="topicVersionRevision">Topic 5010 Version 56.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29100261" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : A Practical Approach to Neonatal Opiate Withdrawal Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33106341" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Neonatal Opioid Withdrawal Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/617308" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The narcotic-dependent mother: fetal and neonatal consequences.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21142534" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Neonatal abstinence syndrome after methadone or buprenorphine exposure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34942181" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Standardizing the Clinical Definition of Opioid Withdrawal in the Neonate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33433576" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Neonatal Abstinence Syndrome and Maternal Opioid-Related Diagnoses in the US, 2010-2017.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33433576" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Neonatal Abstinence Syndrome and Maternal Opioid-Related Diagnoses in the US, 2010-2017.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22291123" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Neonatal drug withdrawal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30091969" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Opioid Use Disorder Documented at Delivery Hospitalization - United States, 1999-2014.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27992619" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Trends in Marijuana Use Among Pregnant and Nonpregnant Reproductive-Aged Women, 2002-2014.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25772211" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Prevalence and patterns of marijuana use among pregnant and nonpregnant women of reproductive age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30150209" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Marijuana Use During Pregnancy and Breastfeeding: Implications for Neonatal and Childhood Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2769510" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Drug screening of meconium in infants of drug-dependent mothers: an alternative to urine testing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2040931" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Neonatal opiate abstinence syndrome in term and preterm infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3348657" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Maternal narcotic abuse and the newborn.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1445130" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Narcotic addiction in pregnancy with adverse maternal and perinatal outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/645651" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Narcotic addiction, pregnancy, and the newborn.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2366131" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Infrequent neonatal opiate withdrawal following maternal methadone detoxification during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12576263" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Pregnancy-related substance use in the United States during 1996-1998.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8355744" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Prevalence and magnitude of perinatal substance exposures in California.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20031369" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Heavy in utero ethanol exposure is associated with the use of other drugs of abuse in a high-risk population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29704852" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Prevalence of alcohol use in pregnant women with substance use disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30694320" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Association Among County-Level Economic Factors, Clinician Supply, Metropolitan or Rural Location, and Neonatal Abstinence Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25070299" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Neonatal abstinence syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23632726" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Association of OPRM1 and COMT single-nucleotide polymorphisms with hospital length of stay and treatment of neonatal abstinence syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20074870" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : OPRM1 SNP (A118G): involvement in disease development, treatment response, and animal models.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24996986" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Epigenetic variation in the mu-opioid receptor gene in infants with neonatal abstinence syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20472252" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Relationship between maternal methadone dose at delivery and neonatal abstinence syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29905586" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Does Maternal Buprenorphine Dose Affect Severity or Incidence of Neonatal Abstinence Syndrome?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26491960" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Maternal Buprenorphine Dose at Delivery and Its Relationship to Neonatal Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22227786" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Neonatal abstinence syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21869765" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Update on the pharmacologic management of neonatal abstinence syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20618243" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Perinatal risk factors for the neonatal abstinence syndrome in infants born to women on methadone maintenance therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19727440" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : The Opioid dependent mother and newborn dyad: non-pharmacologic care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34419619" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Reconceptualizing non-pharmacologic approaches to Neonatal Abstinence Syndrome (NAS) and Neonatal Opioid Withdrawal Syndrome (NOWS): A theoretical and evidence-based approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34600100" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Reconceptualizing non-pharmacologic approaches to Neonatal Abstinence Syndrome (NAS) and Neonatal Opioid Withdrawal Syndrome (NOWS): A theoretical and evidence-based approach. Part II: The clinical application of nonpharmacologic care for NAS/NOWS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5560613" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Neonatal narcotic addiction: 10 year observation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4809795" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Late presentation of drug withdrawal symptoms in newborns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20388645" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Growth restriction in pregnancies of opioid-dependent mothers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30530638" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Neonatal Head Circumference in Newborns With Neonatal Abstinence Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36509817" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Association of medication-assisted treatment and short acting opioids with newborn head circumference and birth weight.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36509817" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Association of medication-assisted treatment and short acting opioids with newborn head circumference and birth weight.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22041255" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Pregnancies exposed to methadone, methadone and other illicit substances, and poly-drugs without methadone: a comparison of fetal neurobehaviors and infant outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8834011" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Neonatal withdrawal syndrome in infants exposed to cocaine and methadone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15283946" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Neonatal abstinence syndrome in methadone-exposed infants is altered by level of prenatal tobacco exposure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21857233" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : The relationship between maternal opioid agonists and psychiatric medications on length of hospitalization for neonatal abstinence syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28768628" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Risk of neonatal drug withdrawal after intrauterine co-exposure to opioids and psychotropic medications: cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31262946" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Increased Severity of Neonatal Abstinence Syndrome Associated With Concomitant Antenatal Opioid and Benzodiazepine Exposure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27889067" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : An Atypical Withdrawal Syndrome in Neonates Prenatally Exposed to Gabapentin and Opioids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36069804" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Gabapentin Use During Pregnancy and Lactation With and Without Concurrent Opioid Exposure: Considerations and Future Directions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17511598" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Sequela of preterm versus term infants born to mothers on a methadone maintenance program: differential course of neonatal abstinence syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17137892" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Exposure to marijuana during pregnancy alters neurobehavior in the early neonatal period.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33240134" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Cannabis Use in Pregnant and Breastfeeding Women: Behavioral and Neurobiological Consequences.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31288542" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Cannabis Teratology Explains Current Patterns of Coloradan Congenital Defects: The Contribution of Increased Cannabinoid Exposure to Rising Teratological Trends.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16143741" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Acute neonatal effects of cocaine exposure during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11711242" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Newborn evaluations of toxicity and withdrawal related to prenatal cocaine exposure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3950828" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Perinatal cerebral infarction and maternal cocaine use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9445497" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Birth outcome from a prospective, matched study of prenatal crack/cocaine use: II. Interactive and dose effects on neurobehavioral assessment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9917443" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Dose-response effect of fetal cocaine exposure on newborn neurologic function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14754949" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Abnormal auditory brainstem response among infants with prenatal cocaine exposure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3397800" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Neonatal neurologic and electroencephalographic effects of intrauterine cocaine exposure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24999039" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Prenatal cocaine effects on brain structure in early infancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25855194" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Prenatal drug exposure affects neonatal brain functional connectivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27242332" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Thalamocortical functional connectivity and behavioral disruptions in neonates with prenatal cocaine exposure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/626072" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : The influence of amphetamine addiction on pregnancy and the newborn infant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4834227" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : The case history of an infant born to an amphetamine-addicted mother.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24588296" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Prenatal methamphetamine exposure and neonatal and infant neurobehavioral outcome: results from the IDEAL study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12584481" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Effects of prenatal methamphetamine exposure on fetal growth and drug withdrawal symptoms in infants born at term.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8354431" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Visual evoked potentials and visual processing in stimulant drug-exposed infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22652562" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Amphetamines, the pregnant woman and her children: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16951010" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : The infant development, environment, and lifestyle study: effects of prenatal methamphetamine exposure, polydrug exposure, and poverty on intrauterine growth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25599434" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Methamphetamines and pregnancy outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20570284" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Intrauterine growth of infants exposed to prenatal methamphetamine: results from the infant development, environment, and lifestyle study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16395620" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Methamphetamine and other substance use during pregnancy: preliminary estimates from the Infant Development, Environment, and Lifestyle (IDEAL) study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29509557" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Effect of Methamphetamine Hydrochloride on Pregnancy Outcome: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29509557" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Effect of Methamphetamine Hydrochloride on Pregnancy Outcome: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/920764" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Effects of antenatal exposure to anorectic drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4396080" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Associations between drugs administered during pregnancy and congenital abnormalities of the fetus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/839382" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Withdrawal symptoms in infants with the fetal alcohol syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7343193" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Symptoms of neonatal ethanol withdrawal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17894421" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: neonatal outcome and congenital malformations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11773648" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Effects of commonly used benzodiazepines on the fetus, the neonate, and the nursing infant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16778707" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : In utero exposure to smoking and newborn neurobehavior: how to assess neonatal withdrawal syndrome?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20414166" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : On categorizing gestational, birth, and neonatal complications following late pregnancy exposure to antidepressants: the prenatal antidepressant exposure syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20414166" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : On categorizing gestational, birth, and neonatal complications following late pregnancy exposure to antidepressants: the prenatal antidepressant exposure syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6470868" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Neonatal ethanol withdrawal: characteristics in clinically normal, nondysmorphic neonates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/830876" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Withdrawal symptoms in neonates from intrauterine exposure to diazepam.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Clinical presentation and management of neonatal abstinence syndrome: an update</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14739371" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Does in utero exposure to heavy maternal smoking induce nicotine withdrawal symptoms in neonates?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24413030" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : In utero exposure to Black Bull chewing tobacco and neonatal nicotine withdrawal: a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23439891" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Prenatal substance abuse: short- and long-term effects on the exposed fetus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34639512" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Neonatal Outcomes after Combined Opioid and Nicotine Exposure in Utero: A Scoping Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22510415" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : [Withdrawal in newborns after exposure to psychotropic medications during pregnancy].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33589723" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Outcomes of mothers and newborns to prenatal exposure to kratom: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28742676" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Committee Opinion No. 711: Opioid Use and Opioid Use Disorder in Pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28742676" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Committee Opinion No. 711: Opioid Use and Opioid Use Disorder in Pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11241040" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Estimates of illicit drug use during pregnancy by maternal interview, hair analysis, and meconium analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25808363" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : UHPLC-MS/MS quantification of buprenorphine, norbuprenorphine, methadone, and glucuronide conjugates in umbilical cord plasma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16281047" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Testing for fetal exposure to illicit drugs using umbilical cord tissue vs meconium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16281047" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Testing for fetal exposure to illicit drugs using umbilical cord tissue vs meconium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30342870" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Umbilical Cord Tissue and Meconium May Not Be Equivalent for Confirming in Utero Substance Exposure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33568363" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Association of first trimester prescription opioid use with congenital malformations in the offspring: population based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25460252" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Infants of opioid-dependent mothers: neurodevelopment at six months.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28709965" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Sensorimotor outcomes in children with prenatal exposure to methadone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28993061" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Risk comparison for prenatal use of analgesics and selected birth defects, National Birth Defects Prevention Study 1997-2011.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28562278" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Maternal Use of Opioids During Pregnancy and Congenital Malformations: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24084542" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Periconceptional use of opioids and the risk of neural tube defects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21345403" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Maternal treatment with opioid analgesics and risk for birth defects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34100263" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Association Between Prenatal Opioid Exposure and Neurodevelopmental Outcomes in Early Childhood: A Retrospective Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35131753" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Prescribed opioid analgesics in early pregnancy and the risk of congenital anomalies: a population-based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33906463" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Cleft Lip and Palate in Infants With Prenatal Opioid Exposure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31306323" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : National Partnership for Maternal Safety: Consensus Bundle on Obstetric Care for Women With Opioid Use Disorder.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
